|
End-of-day quote
NSE India S.E.
30/09/2026
|
5-day change | 1st Jan Change | ||
| 1,943.00 INR | -0.82% |
|
-1.62% | +42.40% |
| 23/09 | Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 | CI |
| 16/09 | Gilead Sciences Expands Licensing Agreements for HIV Treatment | MT |
| Market Cap | 37TCr 384.37Cr 338.48Cr 320.7Cr 289.52Cr 545.68Cr 552.73Cr 3.84TCr 1.48TCr 19TCr 1.44TCr 1.41TCr 60TCr | P/E 2027 * |
31x | P/E 2028 * | 25.1x |
|---|---|---|---|---|---|
| Enterprise Value | 37TCr 391.03Cr 344.34Cr 326.25Cr 294.54Cr 555.13Cr 562.31Cr 3.9TCr 1.5TCr 19TCr 1.47TCr 1.44TCr 61TCr | EV / Sales 2027 * |
3.54x | EV / Sales 2028 * | 3.05x |
| Free-Float |
18.25% | Yield 2027 * |
0.21% | Yield 2028 * | 0.24% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| EMCURE | End-of-day quote | |
Bombay S.E.
| EMCURE | Delayed |
Last Transcript: Emcure Pharmaceuticals Limited
| 1 day | -0.82% | ||
| 1 week | -1.62% | ||
| Current month | +4.73% | ||
| 1 month | +3.94% | ||
| 3 months | +5.06% | ||
| 6 months | +17.57% | ||
| Current year | +42.40% |
| 1 week | 1,907.2 |  | 1,991.4 |
| 1 month | 1,835 | | 2,100.7 |
| Current year | 1,381 | | 2,100.7 |
| 1 year | 1,260 | | 2,100.7 |
| 3 years | 889 | | 2,100.7 |
| 5 years | 889 | | 2,100.7 |
| 10 years | 889 | | 2,100.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 16/04/1981 | |
| Director of Finance/CFO | - | 01/10/2003 | |
| Compliance Officer | - | 04/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 23/07/2001 | |
| Chairman | 75 | 21/09/2026 | |
| Director/Board Member | 49 | 28/07/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.82% | -1.62% | +52.78% | - | 387.26Cr | |
| -1.23% | +1.62% | +53.30% | +117.29% | 1,05600Cr | |
| -0.54% | -0.98% | +43.74% | +71.79% | 64TCr | |
| -0.07% | -0.71% | +13.68% | +77.54% | 47TCr | |
| -1.82% | -0.92% | +74.81% | +43.07% | 37TCr | |
| -0.06% | -3.88% | +34.32% | +40.74% | 34TCr | |
| -0.79% | +2.01% | +19.82% | +28.48% | 28TCr | |
| -1.19% | -1.21% | +9.82% | +12.15% | 25TCr | |
| -0.17% | +4.23% | +49.99% | +58.94% | 23TCr | |
| -0.78% | -0.68% | +35.44% | +102.89% | 19TCr | |
| Average | -0.70% | +0.06% | +38.77% | +61.43% | 38.2TCr | |
| Weighted average by Cap. | -0.83% | +0.30% | +40.88% | +73.24% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 11TCr 110.48Cr 97Cr 92Cr 83Cr 156.84Cr 158.87Cr 1.1TCr 424.4Cr 5.42TCr 414.84Cr 405.79Cr 17TCr | 12TCr 124.83Cr 109.92Cr 104.15Cr 94Cr 177.21Cr 179.5Cr 1.25TCr 479.52Cr 6.12TCr 468.72Cr 458.5Cr 20TCr |
| Net income | 1.19TCr 12Cr 11Cr 10Cr 9.32Cr 18Cr 18Cr 123.58Cr 48Cr 606.83Cr 46Cr 45Cr 1.95TCr | 1.46TCr 15Cr 13Cr 13Cr 11Cr 22Cr 22Cr 151.86Cr 58Cr 745.68Cr 57Cr 56Cr 2.39TCr |
| Net Debt | 638.41Cr 6.66Cr 5.86Cr 5.56Cr 5.02Cr 9.45Cr 9.57Cr 66Cr 26Cr 326.37Cr 25Cr 24Cr 1.05TCr | -327.82Cr -3.42Cr -3.01Cr -2.85Cr -2.58Cr -4.85Cr -4.92Cr -34Cr -13Cr -167.59Cr -13Cr -13Cr -537.29Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | ₹1,943.00 | -0.82% | 71,094 |
| 29/26/29 | ₹1,959.10 | +1.62% | 3,30,808 |
| 28/26/28 | ₹1,927.80 | -1.17% | 39,044 |
| 25/26/25 | ₹1,950.60 | -0.08% | 32,384 |
| 24/26/24 | ₹1,952.10 | -1.49% | 47,459 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EMCURE Stock
Select your edition
All financial news and data tailored to specific country editions
